tisotumab vedotin
tisotumab vedotin: 5 clinical trials tracked.
tisotumab vedotin evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about tisotumab vedotin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (5)
Phase II Study Tisotumab Vedotin in Metastatic or Recurrent Squamous Cell Carcinoma of the Vulva
Primary endpoint: Overall Response Rate
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
Primary endpoint: Objective Response Rate (ORR) in Sacituzumab Tirumotecan Run-in
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Primary endpoint: Overall Survival
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Primary endpoint: Dose escalation: Dose Limiting Toxicities (DLTs)
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Primary endpoint: Confirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G)